There is a balm in Gilead: Idenix’s patent infringed but invalid

No items found.
01 April 2015
Tags
Life

The Journal of Intellectual Property Law and Practice (JIPLP) has published an article by Darren Smyth on a decision by the Patents Court in Idenix Pharmaceuticals, Inc v Gilead Sciences, Inc & Others where Idenix unsuccessfully argued that a cited document constituting novelty-only prior art was not entitled to its priority date due to a procedural defect rather than its substantive disclosure.

To read the JIPLP article in full, click here.

Related articles

EIP recognsied for strategic leadership in patent law at the Professional Services Management Excellence Awards
26 March 2026
EIP has been recognised with two Professional Services Management Excellence Awards 2026, including Excellence in Strategic Leadership and Best in Theme: Leadership. The awards reflect the firm’s commitment to aligning patent expertise with commercial insight, strengthening leadership across the firm and delivering patent strategy that supports investment, growth and high‑value business decisions.
EIP promotes Callum Docherty to Principal in the US
19 March 2026
EIP is pleased to announce the promotion of Callum Docherty to Principal, recognizing his substantial contribution to the firm’s international patent practice and his leadership within EIP’s growing US team.
EIP announces the promotion of Rob Barker to Partner
12 March 2026
EIP is pleased to announce the promotion of Robert Barker to Partner, recognising his significant contribution to the firm’s Digital, Chemistry, Life Sciences, and multidisciplinary patent practice since joining in 2014.